Indoco Remedies has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga, following an inspection of the said facility from September 15 to September 19, 2025.

Speaking in this regard, Aditi Panandikar, Managing Director, Indoco, said, “We are pleased to have received the EIR from the USFDA for our API manufacturing facility located at Patalganga. This further reinforces our commitment to upholding the highest standards of quality and compliance, delivering trusted healthcare solutions to patients worldwide.”